I
f you’ve been vaccinated for COVID-19, chances are pretty high that you’re benefiting from a product made by BioNTech. The German biotech company, co-founded by a husband-and-wife team of scientists, developed the vaccine that became not only the first to earn authorization in the U.S. for COVID-19 in December but also the first ever based on a new technology involving the genetic material mRNA.
In interviews in December and March, co-founders Ugur Sahin and Ozlem Tureci spoke about their whirlwind year and their partnership with U.S. pharmaceutical company Pfizer to test and manufacture the vaccine. Over three days in late March, they also opened up their new manufacturing plant to TIME for the first step-by-step look at how their lifesaving, and potentially pandemic-ending, vaccine is made.
![As Quality Control Lab Manager, Witali Schmidt oversees the testing of all raw materials coming in, as well as the finished product going out. The product produced here goes into the human body, he says. So it's very important that the quality is perfect, that the person only gets the vaccine and nothing besides that.](https://api.time.com/wp-content/uploads/2021/04/luca-locatelli-biontech-baxter-germany-covid-7.jpg?w=1200&quality=85 "As Quality Control Lab Manager, Witali Schmidt oversees the testing of all raw materials coming in, as well as the finished product going out. "The product produced here goes into the human body," he says. "So it's very important that the quality is perfect, that the person only gets the vaccine and nothing besides that."")
When Sahin read a scientific paper in late January 2020 describing the first identified cases of COVID-19 in Wuhan, China, “it was very clear to me that this was not a local outbreak anymore,” he says. “And most likely the virus had already spread worldwide.”
He knew there was no time to waste. But BioNTech, based in Mainz, was then primarily a cancer-vaccine company; after more than a decade of research and development, the company had tested its mRNA-based cancer vaccines in about 400 people, with encouraging results. They were just exploring the possibility of creating vaccines against infectious diseases–specifically an mRNA-based vaccine against flu–when COVID-19 hit.
“[Ugur] convinced all of us, including our board, colleagues and scientific teams, that this was now our calling and we have to follow this mission,” says Tureci. At an emergency meeting, Sahin urged a 40-member team to “move with the speed of light” toward the company’s new goal of developing a COVID-19 vaccine. The team, which grew to more than 200, worked nights and through holidays on Project Lightspeed, and after several weeks had produced 20 candidates. An unprecedented four showed promise in neutralizing the virus. “There was a clear message that this has to be the priority,” says Andreas Kuhn, senior vice president of RNA biochemistry and manufacturing at BioNTech. “Whatever you’re doing right now, kind of forget about it because this is the most important thing now.”
With so little known about the new virus, the team turned to what was known about two related coronaviruses: SARS and MERS. Soon it had a 50,000-step process for building an mRNA vaccine against the new coronavirus, SARS-CoV-2.
![Before pivoting to the COVID-19 vaccine, BioNTech was largely focused on using the new mRNA technology to develop cancer vaccines. What the success of the coronavirus vaccine has now shown is that mRNA is really a proven technology for infectious diseases, says Andreas Kuhn, senior vice president of RNA biochemistry and manufacturing at BioNTech. We haven't forgotten about the cancer patients—the cancer programs are still running as much as it's possible under the current circumstances. We will of course go back. Kuhn was recently vaccinated. It was the first time that I got a vaccine, or any kind of medication, where I was actually involved in making it, he adds. So that was really special.](https://api.time.com/wp-content/uploads/2021/04/luca-locatelli-biontech-baxter-germany-covid-9.jpg?w=700&quality=85 "Before pivoting to the COVID-19 vaccine, BioNTech was largely focused on using the new mRNA technology to develop cancer vaccines. "What the success of the coronavirus vaccine has now shown is that mRNA is really a proven technology for infectious diseases," says Andreas Kuhn, senior vice president of RNA biochemistry and manufacturing at BioNTech. "We haven't forgotten about the cancer patients—the cancer programs are still running as much as it's possible under the current circumstances. We will of course go back." Kuhn was recently vaccinated. "It was the first time that I got a vaccine, or any kind of medication, where I was actually involved in making it," he adds. "So that was really special."")
It begins in a 50-L stainless-steel tank that more closely resembles a beer keg than what you might imagine to be part of a lifesaving bioreactor. Inside are fragments of mRNA coding for the SARS-CoV-2 spike protein, the Achilles’ heel of the virus that the vaccine will exploit. The entire production process happens in a hermetically sealed system, with products from each stage transported to the next via a network of transparent plastic tubing.
Even so, just to be safe, technicians routinely test the air in the manufacturing rooms for any extraneous bacteria or pathogens, and those working with the vaccine regularly tap each gloved finger onto petri dishes filled with agar that can culture for any stray microbes that might have made their way into the facility.
Because mRNA is relatively unstable, it wouldn’t survive in its raw form in the human body. In order to keep the mRNA protected, it’s encased in a fatty bubble using pressurized ethanol–a highly flammable substance. The process happens in one of six 50-L tanks, each in its own sealed-off room. The few people authorized to venture in and out of the rooms put on special static-free shoes to avoid generating an accidental friction spark that could set off an explosion. Five of the tanks are named for team members who were instrumental in developing the process, and the sixth is named Margaret, after the U.K. grandmother who was the first person to receive the vaccine.
Once the ethanol has done its job of creating the mRNA-containing bubbles, it is filtered out. The result is then filtered several times more, eventually ending up as a milky solution that fills 10-L plastic bags. That liquid is shunted to the so-called fill-and-finish phase, where it is purified in tanks and then squirted into sterile vials–each containing up to six doses–that are shipped to clinics around the world.
![Lukas Knof, manufacturing engineer at the fill-and-finish facility operated by Baxter International in Halle. It makes me very proud to work on this product, to help the whole world, Knof says. My first day [working with the BioNTech vaccine], I was really nervous because I had the feeling that the whole world was watching. It was a big day. For Baxter, and for me.](https://api.time.com/wp-content/uploads/2021/04/luca-locatelli-biontech-baxter-germany-covid-13.jpg?w=1200&quality=85 "Lukas Knof, manufacturing engineer at the fill-and-finish facility operated by Baxter International in Halle. "It makes me very proud to work on this product, to help the whole world," Knof says. "My first day [working with the BioNTech vaccine], I was really nervous because I had the feeling that the whole world was watching. It was a big day. For Baxter, and for me."")
BioNTech currently produces 8 million doses of its vaccine every three to seven days at the new Marburg facility that the company purchased from Novartis last fall. (Many lab technicians, most of whom transferred to BioNTech, still wear their old lab coats with the Novartis logo, as there hasn’t been time to order new ones.) Ultimately, the plant will churn out 1 billion doses a year, and BioNTech is working with Pfizer, which oversaw the final human testing that resulted in the vaccine’s authorization in the U.K., the U.S. and elsewhere, to ramp up manufacturing to produce the 2.5 billion doses it committed to providing the world in 2021.
Both companies are quick to point out that their work is not done. Sahin and his team are also keeping an eye on new variants of the virus starting to take hold around the world, and have already developed another vaccine to target those viral versions, and they plan to start testing it soon.
With the success of the COVID-19 mRNA vaccine, Sahin and Tureci see mRNA technology as playing a more dominant role in treating other diseases as well, and are preparing to pick up the work on flu and cancer vaccines that was interrupted by the pandemic. For now, the team is rightfully proud of what it’s accomplished in a very busy year.
“This is a once-in-a-lifetime project,” says Alexander Muik, director of immunomodulators at the company, who was involved in the early stages of developing the vaccine. “Who can say that they’re part of the solution for a pandemic? Only a few people can say that.”
READ more:
